Kestra Advisory Services LLC Reduces Holdings in Cencora, Inc. $COR

Kestra Advisory Services LLC decreased its position in shares of Cencora, Inc. (NYSE:COR) by 15.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,633 shares of the company’s stock after selling 2,390 shares during the period. Kestra Advisory Services LLC’s holdings in Cencora were worth $3,969,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in COR. Resona Asset Management Co. Ltd. boosted its stake in shares of Cencora by 0.6% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 94,813 shares of the company’s stock worth $29,737,000 after purchasing an additional 538 shares during the period. Seelaus Asset Management LLC grew its holdings in Cencora by 3.8% during the 1st quarter. Seelaus Asset Management LLC now owns 1,740 shares of the company’s stock valued at $547,000 after purchasing an additional 63 shares during the last quarter. Staley Capital Advisers Inc. raised its position in Cencora by 0.7% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,127 shares of the company’s stock worth $1,925,000 after purchasing an additional 40 shares during the period. Quantum Portfolio Management LLC bought a new stake in Cencora in the first quarter worth about $488,000. Finally, Eads & Heald Wealth Management lifted its stake in Cencora by 1.2% in the first quarter. Eads & Heald Wealth Management now owns 8,912 shares of the company’s stock worth $2,800,000 after purchasing an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $307.80 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market capitalization of $59.88 billion, a P/E ratio of 23.60, a P/E/G ratio of 1.65 and a beta of 0.58. The company’s 50-day simple moving average is $279.05 and its two-hundred day simple moving average is $317.75. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s payout ratio is 18.40%.

Cencora announced that its board has authorized a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on COR. Citigroup dropped their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Bank of America boosted their price objective on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. William Blair started coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Finally, Robert W. Baird reduced their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.